Подписаться
Old version
Old version
Подтвержден адрес электронной почты в домене meduniv.lviv.ua - Главная страница
Название
Процитировано
Процитировано
Год
250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study
P O'Connor, M Filippi, B Arnason, G Comi, S Cook, D Goodin, HP Hartung, ...
The Lancet Neurology 8 (10), 889-897, 2009
5152009
Placebo-controlled trial of oral laquinimod for multiple sclerosis
G Comi, D Jeffery, L Kappos, X Montalban, A Boyko, MA Rocca, M Filippi
New England Journal of Medicine 366 (11), 1000-1009, 2012
4422012
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial
R Gold, G Giovannoni, K Selmaj, E Havrdova, X Montalban, EW Radue, ...
The Lancet 381 (9884), 2167-2175, 2013
3352013
Three times weekly glatiramer acetate in relapsing–remitting multiple sclerosis
O Khan, P Rieckmann, A Boyko, K Selmaj, R Zivadinov, ...
Annals of neurology 73 (6), 705-713, 2013
2992013
Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings
AJ Coles, JA Cohen, EJ Fox, G Giovannoni, HP Hartung, E Havrdova, ...
Neurology 89 (11), 1117-1126, 2017
2742017
Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy
E Havrdova, DL Arnold, JA Cohen, HP Hartung, EJ Fox, G Giovannoni, ...
Neurology 89 (11), 1107-1116, 2017
2282017
Ibudilast in relapsing-remitting multiple sclerosis: a neuroprotectant?
F Barkhof, HE Hulst, J Drulovic, BMJ Uitdehaag, K Matsuda, R Landin
Neurology 74 (13), 1033-1040, 2010
1622010
Placebo-controlled trial of oral laquinimod in multiple sclerosis: MRI evidence of an effect on brain tissue damage
M Filippi, MA Rocca, E Pagani, N De Stefano, D Jeffery, L Kappos, ...
Journal of Neurology, Neurosurgery & Psychiatry 85 (8), 851-858, 2014
1392014
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial
G Giovannoni, R Gold, K Selmaj, E Havrdova, X Montalban, EW Radue, ...
The Lancet Neurology 13 (5), 472-481, 2014
1052014
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study
DH Miller, RJ Fox, JT Phillips, M Hutchinson, E Havrdova, M Kita, ...
Neurology 84 (11), 1145-1152, 2015
812015
Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials
C Sampaio, J Bronzova, RA Hauser, AE Lang, O Rascol, SV van de Witte, ...
Movement disorders 26 (8), 1464-1476, 2011
522011
The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase III, placebo-controlled study
L Kappos, G Comi, C Confavreux, MS Freedman, AE Miller, TP Olsson, ...
Mult Scler 18 (Suppl 4), 50, 2012
382012
How Does Fingolimod (Gilenya®) Fit in the Treatment Algorithm for Highly Active Relapsing-Remitting Multiple Sclerosis?
F Fazekas, O Bajenaru, T Berger, TH Fabjan, AH Ledinek, G Jakab, ...
Frontiers in neurology 4, 10, 2013
302013
Identification of a 48 kDa form of unconventional myosin 1c in blood serum of patients with autoimmune diseases
S Myronovkij, N Negrych, T Nehrych, MJ Redowicz, S Souchelnytskyi, ...
Biochemistry and biophysics reports 5, 175-179, 2016
282016
Neutrophil-released enzymes can influence composition of circulating immune complexes in multiple sclerosis
S Paryzhak, T Dumych, I Mahorivska, M Boichuk, G Bila, S Peshkova, ...
Autoimmunity 51 (6), 297-303, 2018
272018
Від вірогідної діагностики до ефективної терапії розсіяного склерозу
ТІ Негрич, БВ Сорокін, СК Євтушенко
Міжнародний неврологічний журнал 3 (49), 152-158, 2012
222012
Рассеянный склероз: актуальность проблемы в Украине, современные аспекты иммунопатогенеза, клиники, диагностики и лечения. Украинский междисциплинарный консенсус
НП Волошина, НН Грицай, ИН Дыкан, СК Евтушенко, ТА Кобысь, ...
Новости медицины и фармации, 20-24, 2007
212007
Natalizumab improves ambulation in relapsing− remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM
N Voloshyna, E Havrdova, M Hutchinson, T Nehrych, X You, S Belachew, ...
European Journal of Neurology 22 (3), 570-577, 2015
202015
Primary results of the SELECTION trial of daclizumab HYP in relapsing multiple sclerosis
G Giovannoni, R Gold, K Selmaj, E Havrdova, X Montalban, EW Radue, ...
28th Congress of the European Committee for Treatment and Research in …, 2012
182012
Efficacy and safety results from CARE-MS I: a phase 3 study comparing alemtuzumab and interferon-beta-1a
A Coles, V Brinar, DL Arnold, J Cohen, C Confavreaux, EJ Fox
Program and abstracts of the 5th Joint Triennial Congress of the European …, 2011
172011
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20